123 related articles for article (PubMed ID: 3462325)
1. N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the monkey: neurochemical pathology and regional brain metabolism.
Mitchell IJ; Cross AJ; Sambrook MA; Crossman AR
J Neural Transm Suppl; 1986; 20():41-6. PubMed ID: 3462325
[TBL] [Abstract][Full Text] [Related]
2. [Experimental research on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonian animal models in the rhesus monkey and C57 black mouse].
Chen S
Zhonghua Yi Xue Za Zhi; 1990 May; 70(5):252-4, 18. PubMed ID: 2168792
[TBL] [Abstract][Full Text] [Related]
3. Sites of the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the macaque monkey include the ventral tegmental area and the locus coeruleus.
Mitchell IJ; Cross AJ; Sambrook MA; Crossman AR
Neurosci Lett; 1985 Oct; 61(1-2):195-200. PubMed ID: 3878482
[TBL] [Abstract][Full Text] [Related]
4. Unilateral MPTP-induced parkinsonism in monkeys. A quantitative autoradiographic study of dopamine D1 and D2 receptors and re-uptake sites.
Przedborski S; Jackson-Lewis V; Popilskis S; Kostic V; Levivier M; Fahn S; Cadet JL
Neurochirurgie; 1991; 37(6):377-82. PubMed ID: 1780015
[TBL] [Abstract][Full Text] [Related]
5. Alterations of the central noradrenergic system in MPTP-induced monkey parkinsonism.
Miyoshi R; Kito S; Ishida H; Katayama S
Res Commun Chem Pathol Pharmacol; 1988 Oct; 62(1):93-102. PubMed ID: 2849789
[TBL] [Abstract][Full Text] [Related]
6. MRI detects acute degeneration of the nigrostriatal dopamine system after MPTP exposure in hemiparkinsonian monkeys.
Miletich RS; Bankiewicz KS; Quarantelli M; Plunkett RJ; Frank J; Kopin IJ; Di Chiro G
Ann Neurol; 1994 Jun; 35(6):689-97. PubMed ID: 8210225
[TBL] [Abstract][Full Text] [Related]
7. Alterations in dopamine uptake sites and D1 and D2 receptors in cats symptomatic for and recovered from experimental parkinsonism.
Frohna PA; Rothblat DS; Joyce JN; Schneider JS
Synapse; 1995 Jan; 19(1):46-55. PubMed ID: 7709343
[TBL] [Abstract][Full Text] [Related]
8. Changes in brain catecholamines and dopamine uptake sites at different stages of MPTP parkinsonism in monkeys.
Alexander GM; Schwartzman RJ; Brainard L; Gordon SW; Grothusen JR
Brain Res; 1992 Aug; 588(2):261-9. PubMed ID: 1356591
[TBL] [Abstract][Full Text] [Related]
9. Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson's disease.
Mavridis M; Degryse AD; Lategan AJ; Marien MR; Colpaert FC
Neuroscience; 1991; 41(2-3):507-23. PubMed ID: 1870701
[TBL] [Abstract][Full Text] [Related]
10. Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Mitchell IJ; Clarke CE; Boyce S; Robertson RG; Peggs D; Sambrook MA; Crossman AR
Neuroscience; 1989; 32(1):213-26. PubMed ID: 2586750
[TBL] [Abstract][Full Text] [Related]
11. [Intrathecal infusion of brain-derived neurotrophic factor protects nigral dopaminergic neurons from degenerative changes in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced monkey parkinsonian model].
Takeda M
Hokkaido Igaku Zasshi; 1995 Nov; 70(6):829-38. PubMed ID: 8582706
[TBL] [Abstract][Full Text] [Related]
12. Changes in local cerebral glucose utilization associated with Parkinson's syndrome induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the primate.
Porrino LJ; Burns RS; Crane AM; Palombo E; Kopin IJ; Sokoloff L
Life Sci; 1987 Apr; 40(17):1657-64. PubMed ID: 3494179
[TBL] [Abstract][Full Text] [Related]
13. Overlesioned hemiparkinsonian non human primate model: correlation between clinical, neurochemical and histochemical changes.
Oiwa Y; Eberling JL; Nagy D; Pivirotto P; Emborg ME; Bankiewicz KS
Front Biosci; 2003 Sep; 8():a155-66. PubMed ID: 12957824
[TBL] [Abstract][Full Text] [Related]
14. A simple quantitative bradykinesia test in MPTP-treated mice.
Ogawa N; Hirose Y; Ohara S; Ono T; Watanabe Y
Res Commun Chem Pathol Pharmacol; 1985 Dec; 50(3):435-41. PubMed ID: 3878557
[TBL] [Abstract][Full Text] [Related]
15. Metabolic mapping of the oculomotor system in MPTP-induced parkinsonian monkeys.
Ho VW; Porrino LJ; Crane AM; Burns RS; Kopin IJ; Sokoloff L
Ann Neurol; 1988 Jan; 23(1):86-9. PubMed ID: 3257855
[TBL] [Abstract][Full Text] [Related]
16. Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys.
Forno LS; Langston JW; DeLanney LE; Irwin I; Ricaurte GA
Ann Neurol; 1986 Oct; 20(4):449-55. PubMed ID: 3024555
[TBL] [Abstract][Full Text] [Related]
17. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey.
Pifl C; Schingnitz G; Hornykiewicz O
Neuroscience; 1991; 44(3):591-605. PubMed ID: 1754053
[TBL] [Abstract][Full Text] [Related]
18. Neural mechanisms mediating 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-induced parkinsonism in the monkey: relative contributions of the striatopallidal and striatonigral pathways as suggested by 2-deoxyglucose uptake.
Mitchell IJ; Cross AJ; Sambrook MA; Crossman AR
Neurosci Lett; 1986 Jan; 63(1):61-5. PubMed ID: 3485267
[TBL] [Abstract][Full Text] [Related]
19. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
Rioux L; Frohna PA; Joyce JN; Schneider JS
Mov Disord; 1997 Mar; 12(2):148-58. PubMed ID: 9087972
[TBL] [Abstract][Full Text] [Related]
20. Serotonin 5-HT(1A) receptor expression is selectively enhanced in the striosomal compartment of chronic parkinsonian monkeys.
Frechilla D; Cobreros A; Saldise L; Moratalla R; Insausti R; Luquin M; Del Río J
Synapse; 2001 Mar; 39(4):288-96. PubMed ID: 11169778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
